Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

CONTEXT.—: Minimal residual disease (MRD) is a major prognostic factor in multiple myeloma, although validated technologies are limited. OBJECTIVE.—: To standardize the performance of the LymphoTrack next-generation sequencing (NGS) assays (Invivoscribe), targeting clonal immunoglobulin rearrangemen...

Full description

Bibliographic Details
Main Authors: Alcoceba, M. (Author), Chillón, C. (Author), Flores-Montero, J. (Author), García-Álvarez, M. (Author), García-Sanz, R. (Author), González, M. (Author), González-Calle, V. (Author), Gutiérrez, N.C (Author), Huang, Y. (Author), Hutt, K. (Author), Jacobsen, A. (Author), Jiménez, C. (Author), Medina, A. (Author), Miller, J. (Author), Orfao, A. (Author), Prieto-Conde, I. (Author), Puig, N. (Author), Sarasquete, M.E (Author), Vigil, E. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
genetics
high throughput sequencing
High-Throughput Nucleotide Sequencing
human
Humans
minimal residual disease
multiple myeloma
Multiple Myeloma
Neoplasm, Residual
nerve growth factor
Nerve Growth Factor
procedures
reproducibility
Reproducibility of Results
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items